Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed grade 1, 2, or 3 follicular non-Hodgkin lymphoma
• * Stage II, III, or IV disease (according to the Ann Arbor staging system)
• CD20-positive disease
• Initial disease bulk ≤ 10 cm
• In first or second relapse after prior treatment with a rituximab-containing chemotherapy regimen (R-chemo) or chemotherapy alone
• * Relapse must have occurred ≥ 6 months after completion of R-chemo
• * Relapse that occurred \< 6 months after completion of chemotherapy alone allowed
• Has at least one of the following symptoms requiring initiation of treatment:
• * Nodal mass \> 5 cm in its greater diameter
• * B symptoms
• * Elevated serum lactate dehydrogenase (LDH) or β2-microglobulin
• * Involvement of ≥ 3 nodal sites (each with a diameter \> 3 cm)
• * Symptomatic splenic enlargement
• * Compressive syndrome
• No primary refractory disease
• No large pleural or peritoneal effusions
• No CNS disease
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 6 months
• Absolute granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 1,000/mm³
• Serum creatinine \< 1.5 times upper limit of normal (ULN)
• Total bilirubin \< 1.5 times ULN
• AST \< 5 times ULN
• No active obstructive hydronephrosis
• No evidence of active infection requiring IV antibiotics
• No advanced heart disease or other serious illness that would preclude study evaluation
• No known HIV infection
• No human anti-mouse antibody (HAMA) reactivity
• No known hypersensitivity to murine antibodies or proteins
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 12 months after completion of study treatment
• No other prior malignancy, except for adequately treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 4 weeks since prior investigational drugs and recovered
• No prior radioimmunotherapy